This course has expired. You can still review the content but course credit is no longer available.
The target audience for this program is retina specialists and general ophthalmologists specializing in the treatment of retina disease.
Upon completion of this activity, the participant should be able to:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC and Retina Today and New Retina MD.
Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit.™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing medical education activity is supported through an educational grant from Santen Pharmaceutical Co., Ltd.
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty members have the following financial relationships with commercial interests:
Thomas Albini, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: AbbVie, Inc.; Allergan, Inc; Bausch + Lomb; and Santen Pharmaceutical Co., Ltd.
Steven Yeh, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bausch+ Lomb; Clearside Biomedical, Inc.; and Santen Pharmaceutical Co., Ltd.
Grant/Research Support: Alcon Research Institute; Clearside Biomedical, Inc.; NIH; and Xoma Ltd.
Cheryl Cavanaugh, MS, Evolve Medical Education LLC; Emily Feinman, Retina Today and New Retina MD; and Michelle Dalton, Writer; have no real or apparent conflicts of interest to report.
Rishi Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech, Inc; Regeneron Pharmaceuticals, Inc.; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.